UPDATED: Amylyx shares routed on skeptical adcomm docs — but did the FDA leave an open door on unmet ALS need? - Endpoints News

The FDA released its briefing documents for Wednesday’s advisory committee to discuss Amylyx Pharmaceuticals’ ALS drug, and the initial impression appears to bode poorly for the biotech — at least on the data. Agency statisticians called into question the com…

Oncolytic virus biotech Replimune put out a comprehensive pipeline update Wednesday morning, indicating its lead program remains on its development track. But questions lingered regarding a follow-up… [+549 chars]

full article...